Renal Regulation of Acid-Base Balance

Acid-base homeostasis requires that the rate of acid or base excretion match the rate of acid or base production, so that plasma bicarbonate concentration and pH remain stable. Cellular metabolism generates roughly 15,000–20,000 mmol of CO₂ per day (volatile acid, exhaled by the lungs) and, from the oxidation of sulfur-containing amino acids and phosphate esters, roughly 50–100 mmol of nonvolatile ("fixed") acid per day, mainly sulfuric and phosphoric acid, that only the kidneys can eliminate. Every mole of fixed acid produced consumes one mole of buffer base (chiefly plasma HCO₃⁻), so without renal regeneration of bicarbonate the buffer reserve would be exhausted within about a day. The kidney's contribution to acid-base balance is best understood as three logically separate, though anatomically overlapping, functions. First is bicarbonate reabsorption: essentially all of the roughly 4,500 mmol of HCO₃⁻ filtered daily (filtered load = GFR × plasma [HCO₃⁻] ≈ 180 L/day × 24–25 mmol/L) must be retrieved, or the body would hemorrhage its buffer base into the urine and become acidotic. Second is titratable acid excretion: hydrogen ions secreted into the tubule fluid combine with filtered buffers, chiefly phosphate (HPO₄²⁻ + H⁺ → H₂PO₄⁻), allowing the urine to carry away acid without its free H⁺ concentration becoming lethally high. Third is ammonium excretion: proximal tubule cells synthesize ammonia from glutamine, and the resulting NH₄⁺ is excreted in the urine, carrying with it hydrogen ion equivalents and, critically, generating "new" bicarbonate that enters the blood — the kidney's only mechanism for actually replenishing buffer base rather than merely conserving it. A key conceptual distinction: reabsorbing filtered bicarbonate does not add any new base to the blood — it simply prevents a loss. Only titratable acid excretion and ammonium excretion produce net acid excretion, defined as:

Net acid excretion (NAE) = (urinary titratable acid + urinary NH₄⁺) − urinary HCO₃⁻ Under normal conditions NAE ≈ 70 mmol/day, matching the daily fixed acid load, of which ammonium excretion typically contributes about two-thirds and titratable acid about one-third; during acidosis, ammoniagenesis can increase several-fold and becomes overwhelmingly dominant.

Bicarbonate reabsorption — the proximal tubule workhorse. Roughly 80–90% of filtered HCO₃⁻ is reclaimed in the proximal convoluted tubule, with most of the remainder recovered in the thick ascending limb and the fine-tuning done in the distal nephron. Filtered HCO₃⁻ cannot cross the apical membrane directly in significant amounts. Instead, the proximal tubule cell secretes H⁺ into the lumen, predominantly via the Na⁺/H⁺ exchanger NHE3 (about 2/3 of secretion) and a vacuolar H⁺-ATPase (about 1/3), both energized indirectly by the basolateral Na⁺-K⁺-ATPase that maintains the low intracellular Na⁺ gradient driving NHE3. In the lumen, secreted H⁺ combines with filtered HCO₃⁻ to form carbonic acid, H₂CO₃, which would dehydrate to CO₂ and H₂O far too slowly to keep pace with tubular flow. This is where carbonic anhydrase type IV, anchored to the luminal brush-border membrane, becomes essential: it catalyzes near-instantaneous dehydration of H₂CO₃ to CO₂ and H₂O. The lipid-soluble CO₂ diffuses freely into the cell, where cytoplasmic carbonic anhydrase type II catalyzes the reverse reaction, rehydrating CO₂ to H₂CO�3, which dissociates into H⁺ (recycled for secretion) and HCO₃⁻. This intracellular HCO₃⁻ exits across the basolateral membrane into peritubular blood, chiefly via the electrogenic Na⁺-HCO₃⁻ cotransporter NBCe1, which moves 1 Na⁺ with 3 HCO₃⁻ ions. The net effect: for every filtered HCO₃⁻ ion "reabsorbed," a different HCO₃⁻ ion (synthesized inside the cell from CO₂ and H₂O) actually enters the blood — the filtered bicarbonate itself is destroyed as CO₂ in the lumen and regenerated. This CO₂-recycling shuttle explains why the drug acetazolamide, a carbonic anhydrase inhibitor, causes a brisk bicarbonate diuresis: without luminal CA activity, H₂CO₃ dehydration is too slow, luminal H⁺ and HCO₃⁻ cannot be processed, and both are lost in urine, producing a mild metabolic acidosis.

Titratable acid — buffering H⁺ on filtered phosphate. Once virtually all filtered HCO₃⁻ has been consumed (reclaimed) in the early proximal tubule, any further H⁺ secreted downstream — in the late proximal tubule, thick ascending limb, and especially the distal nephron — has no bicarbonate left to react with. Instead it protonates other filtered buffers, chiefly the phosphate couple HPO₄²⁻/H₂PO₄⁻ (pKa ≈ 6.8, well matched to urine pH) and to a lesser extent creatinine and urate. This titration of urinary buffers is what "titratable acid" measures operationally: the amount of strong base (NaOH) needed to titrate a urine sample back to plasma pH (7.4). Because filtered phosphate is finite (determined by dietary phosphate intake and GFR, typically ~30–40 mmol/day), titratable acid excretion has a hard ceiling and cannot be upregulated much in response to acid load — this is the central limitation that makes ammonium excretion indispensable.

Ammonium excretion — the adjustable acid-disposal system. Proximal tubule cells metabolize glutamine (extracted from both blood and filtrate) via glutaminase and glutamate dehydrogenase, producing two NH₄⁺ ions and one α-ketoglutarate²⁻ ion per glutamine molecule. The α-ketoglutarate is further metabolized to CO₂ and, ultimately, glucose (gluconeogenesis) or is oxidized completely; this metabolism consumes two H⁺ equivalents, which is chemically identical to generating two new HCO₃⁻ ions that cross the basolateral membrane into blood. The NH₄⁺ is secreted into the lumen partly via NHE3 (which can transport NH₄⁺ in place of H⁺) and is carried down the nephron. Critically, NH₄⁺ handling involves a countercurrent trapping mechanism in the medulla analogous to urea recycling. In the thick ascending limb, NH₄⁺ substitutes for K⁺ on the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) and is reabsorbed, then accumulates in the medullary interstitium. Some interstitial NH₄⁺ dissociates to NH₃ (a gas, pKa ≈ 9.2) plus H⁺; the lipid-soluble NH₃ diffuses into the collecting duct lumen, where it is "trapped" by combining with H⁺ secreted there by intercalated cells, reforming NH₄⁺ (charged, membrane-impermeant) that is excreted in urine. This nonionic diffusion trapping — NH₃ diffuses down its concentration gradient, H⁺ secretion locally converts it to NH₄⁺ and maintains the gradient — lets the collecting duct excrete large quantities of ammonium without needing a dedicated NH₄⁺ transporter for most of the flux. In chronic metabolic acidosis, proximal tubule glutamine extraction and ammoniagenic enzyme expression increase several-fold over days, driven partly by cell acidification itself and partly by hormonal signals, raising urinary NH₄⁺ excretion from a baseline of ~30–40 mmol/day to 200–300 mmol/day, the single most important adaptive response to sustained acid loads.

Distal fine-tuning — intercalated cells. The final urine acidity and the last few percent of bicarbonate handling are controlled by two specialized cell types studding the collecting duct epithelium, interspersed among the principal cells that handle Na⁺/K⁺/water transport.

• Type A (α) intercalated cells secrete H⁺ into the lumen via an apical H⁺-ATPase and an H⁺/K⁺-ATPase (which also reabsorbs K⁺, relevant to the K⁺–H⁺ interactions seen clinically), while reabsorbing HCO₃⁻ across the basolateral membrane via the Cl⁻/HCO₃⁻ exchanger AE1. These cells can generate a steep H⁺ gradient, dropping luminal pH to as low as 4.5 (a thousand-fold H⁺ gradient relative to blood), which is what makes titratable acid and NH₄⁺ trapping quantitatively effective.
• Type B (β) intercalated cells run the system in reverse during alkali loads: they secrete HCO₃⁻ apically via pendrin (a Cl⁻/HCO₃⁻ exchanger) and extrude H⁺ basolaterally, providing a mechanism for renal bicarbonate excretion when the body needs to get rid of excess base.

The balance between type A and type B activity is regulated by systemic acid-base status, aldosterone, and dietary Cl⁻ delivery, giving the distal nephron remarkable flexibility to shift from net acid excretion to net base excretion as physiological conditions demand.

Pitts and Alexander (1945) — direct measurement of renal acid handling. Robert Pitts and John Alexander performed classic clearance studies in dogs, systematically measuring urinary excretion of titratable acid, ammonium, and bicarbonate under varying acid-base states while simultaneously sampling arterial and renal venous blood. By varying the acid or alkali load given to the animals and measuring urine pH, titratable acid (by direct titration with NaOH to plasma pH), and ammonia (chemically assayed), they established the quantitative accounting equation for net acid excretion (NAE = titratable acid + NH₄⁺ − HCO₃⁻) that remains the operational definition used clinically today. Their work showed that during induced acidosis, urinary ammonium excretion rose dramatically — several-fold — while titratable acid rose only modestly and reached a plateau, demonstrating that ammoniagenesis, not phosphate buffering, is the adjustable, high-capacity component of renal acid disposal. This was among the first quantitative demonstrations that the kidney does not merely "excrete acid" but actively synthesizes ammonia to expand its excretory capacity.

Pitts, Ayer, and Schiess (1949) and later micropuncture studies — the source of urinary ammonia. Using arteriovenous difference measurements across the kidney and later free-flow micropuncture of individual nephron segments (pioneered by Gertrude and Carl Gottschalk and later refined extensively through the 1960s–1980s), physiologists demonstrated that renal ammonia is synthesized de novo from glutamine extracted by the proximal tubule, rather than merely filtered from plasma ammonia. Renal venous blood ammonia concentration was shown to be far too low to account for the ammonia appearing in urine; instead, isotopically labeled glutamine (¹⁵N-labeled) infused into the renal artery appeared as labeled ammonium in the urine, directly proving renal glutamine metabolism as the ammoniagenic source. Micropuncture sampling along the proximal tubule showed ammonia concentration in tubular fluid rising progressively along the proximal convoluted tubule length, consistent with local synthesis and secretion rather than simple filtration (filtered ammonia would be diluted, not concentrated, as water is reabsorbed if there were no additional secretion — the observed concentration rise exceeded what reabsorption of water alone would produce).

Carbonic anhydrase inhibition — Pitts and colleagues; and the acetazolamide studies of the 1950s. The discovery that sulfonamide derivatives (culminating in acetazolamide) potently inhibit carbonic anhydrase, made by Roughton, Davenport, and coworkers investigating erythrocyte CO₂ transport, was rapidly applied to the kidney. When acetazolamide was administered to experimental animals and humans, it produced a marked bicarbonate diuresis — urine pH rose toward neutrality, urinary HCO₃⁻ excretion increased sharply, and a mild hyperchloremic metabolic acidosis developed, exactly as predicted if luminal CA-IV is required for rapid H₂CO₃ dehydration during bicarbonate reclamation. This pharmacological experiment provided direct causal evidence — not just correlation — that carbonic anhydrase activity is rate-limiting for proximal bicarbonate reabsorption, confirming the CO₂-recycling mechanism rather than any hypothetical direct luminal HCO₃⁻ transporter.

Free-flow micropuncture measurements of tubular fluid/plasma bicarbonate ratios. Using micropuncture (a technique in which fine glass pipettes sample fluid directly from individual nephron segments in vivo, developed by Alfred Richards in the 1920s and refined by Gottschalk and others), researchers measured the ratio of tubular fluid to plasma bicarbonate concentration (TF/P HCO₃⁻) at successive points along the proximal tubule. This ratio fell steeply from 1.0 at Bowman's capsule to about 0.1–0.2 by the end of the proximal convoluted tubule, directly demonstrating that the bulk of filtered bicarbonate disappears from tubular fluid in this segment — quantitatively confirming what stop-flow and clearance experiments had inferred indirectly, and pinpointing the proximal tubule (rather than distal segments) as the primary site of bicarbonate reclamation.

Example 1 — Calculating filtered load, reabsorption, and net acid excretion in chronic metabolic acidosis. A patient with GFR = 100 mL/min and plasma [HCO₃⁻] = 24 mmol/L is compared to the same patient after several days of a low-carbohydrate, high-protein diet that has dropped plasma [HCO₃⁻] to 18 mmol/L (a compensated metabolic acidosis) while GFR remains 100 mL/min. Filtered load of HCO₃⁻ before diet: 100 mL/min × 24 mmol/L = 2,400 mmol/min... converting to daily volume (GFR ≈ 144 L/day): 144 L/day × 24 mmol/L = 3,456 mmol/day filtered. After the diet (plasma HCO₃⁻ = 18 mmol/L, assuming GFR unchanged): 144 L/day × 18 mmol/L = 2,592 mmol/day filtered — a smaller filtered load, consistent with less bicarbonate available to reabsorb, but virtually all of it is still reclaimed (urine bicarbonate excretion remains near zero in steady-state acidosis; the kidney does not "dump" the remaining bicarbonate — it conserves it maximally). Meanwhile, net acid excretion must rise to match the increased fixed acid production from protein metabolism. Suppose measured urine values are:

NAE (baseline) = 25 + 35 − 2 = 58 mmol/day NAE (acidosis) = 35 + 180 − 0 = 215 mmol/day The nearly six-fold rise in ammonium excretion, versus a modest 40% rise in titratable acid (which is capped by filtered phosphate), illustrates precisely the Pitts–Alexander finding: ammoniagenesis is the kidney's adjustable variable for handling variable acid loads, while titratable acid excretion is a relatively fixed, buffer-limited quantity. Over several days this elevated NAE regenerates bicarbonate stores and returns plasma pH toward normal, even though plasma [HCO₃⁻] settles at a new, lower steady-state value characteristic of compensated metabolic acidosis.

Example 2 — Reasoning through a clinical acid-base disturbance: renal tubular acidosis type II versus type I. A 30-year-old presents with chronic hyperchloremic metabolic acidosis (normal anion gap), plasma [HCO₃⁻] = 16 mmol/L, and urine pH measured at 5.2. A carbonic anhydrase inhibitor challenge and fractional excretion of bicarbonate testing reveal that when plasma HCO₃⁻ is raised toward normal by infusion, this patient spills large amounts of bicarbonate into urine (fractional excretion of HCO₃⁻ > 15%), but once plasma HCO₃⁻ falls back to her low steady-state value, her urine pH can still fall appropriately below 5.5. Interpretation: this pattern is diagnostic of proximal (type II) renal tubular acidosis — a defect in proximal tubule bicarbonate reabsorption (e.g., due to NHE3 or NBCe1 dysfunction, or generalized proximal tubule disease such as Fanconi syndrome). Because the proximal tubule cannot reclaim the normal ~85% of filtered HCO₃⁻, bicarbonate escapes into more distal segments faster than the smaller-capacity distal nephron can recover it, causing bicarbonaturia and a falling plasma HCO₃⁻. Crucially, once plasma HCO₃⁻ has fallen enough that the reduced filtered load no longer exceeds the proximal tubule's (defective but nonzero) reabsorptive capacity, the tubule reabsorbs essentially all the (now smaller) filtered bicarbonate, and the distal nephron — which is functionally normal in type II RTA — can still acidify the urine appropriately, explaining the low urine pH at the new steady state. Contrast this with distal (type I) RTA, in which the defect lies in the type A intercalated cell's H⁺-ATPase or H⁺/K⁺-ATPase (or in the H⁺ back-leak due to abnormal collecting duct permeability). Here urine pH remains inappropriately high (>5.5) even during systemic acidosis, because the distal nephron cannot generate the steep H⁺ gradient needed to trap NH₃ and titrate phosphate — regardless of how low plasma bicarbonate falls. Distinguishing these two entities by the behavior of urine pH under varying plasma bicarbonate is a direct clinical application of the proximal-versus-distal division of labor described in the mechanism section, and it also explains why type I RTA carries a much higher risk of nephrocalcinosis and kidney stones (persistently alkaline urine promotes calcium phosphate precipitation) whereas type II RTA does not.

Robert Franklin Pitts (1908–1977) was an American renal physiologist whose systematic clearance and arteriovenous-difference studies in the 1930s–1950s established the quantitative framework for renal acid-base physiology still used today. Trained in physiology at Cornell and later chairing physiology at Cornell University Medical College, Pitts combined meticulous whole-kidney clearance methodology with an insistence on mass-balance accounting — measuring not just what appeared in urine, but what disappeared from arterial blood and appeared in renal venous blood, so that every mole of acid or base could be tracked. His 1971 monograph "Physiology of the Kidney and Body Fluids" became a standard reference precisely because his experiments, unlike many contemporaries', were designed from the outset to yield exact quantitative equations (like the NAE formula) rather than qualitative descriptions.

Understanding renal acid-base handling underlies the diagnosis and management of renal tubular acidoses (types I, II, and IV), each traceable to a specific defect in the mechanisms described above — proximal HCO₃⁻ reabsorption, distal H⁺ secretion, or aldosterone-dependent acid secretion respectively — and each treated with tailored alkali replacement and, in type IV, mineralocorticoid or dietary potassium management. Carbonic anhydrase inhibitors (acetazolamide) remain in clinical use for glaucoma, altitude sickness prophylaxis, and as adjunct diuretics, all exploiting the mechanism first elucidated through renal bicarbonate physiology. In chronic kidney disease, progressive loss of nephron mass reduces both ammoniagenic capacity and titratable acid excretion, producing the metabolic acidosis of advanced CKD; this observation underlies current clinical trials and guidelines examining oral alkali (sodium bicarbonate) supplementation to slow CKD progression, since chronic acidosis itself promotes tubulointerstitial injury and muscle protein catabolism. In critical care, understanding net acid excretion capacity guides interpretation of the urine anion gap and urine osmolar gap as bedside surrogates for urinary ammonium excretion when direct assay is unavailable, helping distinguish renal versus extrarenal causes of metabolic acidosis at the bedside. Finally, the ammoniagenesis pathway is a target of ongoing research in hepatic encephalopathy and in understanding how metabolic acidosis accelerates bone demineralization (via buffering of acid by skeletal calcium carbonate), connecting renal acid-base physiology to endocrinology, nephrology, critical care, and skeletal biology alike.

Ask the tutor: How would a sudden drop in plasma potassium (hypokalemia) alter renal ammoniagenesis and net acid excretion?